Ensuring the safety of blood products: AABB takes worldwide view
This article was originally published in Clinica
Executive Summary
The blood bank industry's focus shifted from West Nile virus in 2003 to bacterial screening and automation in 2004. That was one of the key messages conveyed to delegates at the annual AABB meeting in October. The event, in Baltimore, Maryland, drew 6,774 attendees, the highest number since 1997, and hosted 519 exhibitors, representing 190 different companies. Safer blood transfusions, donor recruitment/retention programmes and emerging technologies were other significant themes at the conference, write Kerri Weinert, Carrie Cresenzi and Emily Rizza, of US consultancy Boston Biomedical Consultants (BBC)*.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.